gestonorone-caproate and Urination-Disorders

Clinical trials with gestonorone led to favourable results in 65% of the patients. The drug is recommended particularly to patients in stage I or II of prostatic adenoma. It is justified to prescribe this treatment to high risk patients who cannot be operated because of their serious conditions. An objective assessment of the effect of the drug was possible by means of urodynamic and ultrasound tests which detected also fewer latent changes suggesting a continuation or repetition of the treatment.

Topics: Aged; Clinical Trials as Topic; Gestonorone Caproate; Humans; Male; Middle Aged; Prostatic Hyperplasia; Ultrasonics; Urination Disorders; Urodynamics

A study was carried out in 30 male patients with benign prostate hyperplasia to assess the effectiveness of treatment with a progestational agent, gestonorone caproate (200 mg), given intramucularly every 7 days over a period of 2 to 3 months. The results showed definite subjective and objective improvement after treatment. Residual urine determination diminished significantly after therapy in 78% of the cases completing the study; uroflometry also showed improvement. There appeared to be some reduction in the degree of occlusion of the urethral lumen in at least 13(65%) out of 20 patients given follow-up cystopanendoscopy after 6 months. This result was further supported by improvement in urinary flow rates and uroflometrograms in the same patients. The only adverse effect of treatment noted was the development of impotency in 21 patients.

Topics: Aged; Cystoscopy; Drug Evaluation; Erectile Dysfunction; Gestonorone Caproate; Humans; Male; Middle Aged; Prostatic Hyperplasia; Urination; Urination Disorders